AptaBio Therapeutics Inc

AptaBio Therapeutics Inc. is a biopharmaceutical company that develops platform-based drugs for intractable diseases. Its platforms include an oxidative stress modulation platform for therapeutic agents targeting diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers; a cancer-associated fibroblast control platform for new anticancer drugs; and an aptamer-drug conjugate platform for intractable anticancer drugs with high unmet medical needs. The company also offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX reagents for transfecting DNA or RNA into eukaryotic cells. Founded in 2009, it is based in Yongin-si, South Korea.